Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada.
Aged
Amiodarone
/ adverse effects
Anti-Arrhythmia Agents
/ adverse effects
Anticoagulants
/ adverse effects
Atrial Fibrillation
/ diagnosis
Canada
/ epidemiology
Clinical Decision-Making
Coronary Artery Bypass
/ adverse effects
Female
Hemorrhage
/ chemically induced
Humans
Male
Middle Aged
Retrospective Studies
Risk Assessment
Risk Factors
Stroke
/ diagnosis
Time Factors
Treatment Outcome
United States
/ epidemiology
amiodarone
anticoagulation
atrial fibrillation
coronary artery bypass grafting
stroke
Journal
The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
18
09
2019
revised:
14
01
2020
accepted:
20
01
2020
pubmed:
22
3
2020
medline:
3
8
2021
entrez:
22
3
2020
Statut:
ppublish
Résumé
We sought to elucidate national practice patterns regarding anticoagulation and antiarrhythmic medication use at discharge and examine short-term patient outcomes. In this retrospective cohort study, we analyzed the data of patients from the Society of Thoracic Surgeons Adult Cardiac Surgery Database from July 2011 to June 2018 who underwent first-time isolated coronary artery bypass graft surgery (CABG) and developed new post-CABG atrial fibrillation (AF) without significant complications. In total, 166,747 patients met study criteria. We examined 30-day outcomes. In total, 166,747 patients were analyzed and divided into 4 groups based on discharge medications: amiodarone with or without anticoagulation, anticoagulation alone, and neither. Demographic characteristics were similar among the 4 groups. In total, 25.7% of patients were discharged on anticoagulation with an average CHA Post-CABG anticoagulation for new AF is associated with increased bleeding and no difference in stroke at 30 days. Prospective randomized studies are needed to formalize safe and efficacious short- and long-term management strategies.
Identifiants
pubmed: 32197901
pii: S0022-5223(20)30408-6
doi: 10.1016/j.jtcvs.2020.01.077
pmc: PMC7434648
mid: NIHMS1589735
pii:
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Anticoagulants
0
Amiodarone
N3RQ532IUT
Types de publication
Journal Article
Multicenter Study
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
616-624.e3Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL069749
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Références
Ann Thorac Surg. 2009 Jul;88(1 Suppl):S2-22
pubmed: 19559822
Am J Med. 2017 Jul;130(7):773-779
pubmed: 28344142
Medicine (Baltimore). 2015 May;94(19):e849
pubmed: 25984674
J Heart Valve Dis. 2012 Jan;21(1):78-87
pubmed: 22474747
J Am Soc Echocardiogr. 2009 Feb;22(2):212.e1-3
pubmed: 19187857
Ann Intern Med. 2010 Dec 7;153(11):703-9
pubmed: 21135293
Ann Thorac Surg. 2005 Jan;79(1):113-6
pubmed: 15620926
J Am Coll Cardiol. 2008 Feb 26;51(8):793-801
pubmed: 18294562
JAMA Cardiol. 2018 May 1;3(5):417-424
pubmed: 29590304
Ann Thorac Surg. 2009 Jul;88(1 Suppl):S43-62
pubmed: 19559824
J Thorac Cardiovasc Surg. 2014 Sep;148(3):772-91
pubmed: 25129583
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132
pubmed: 30703431
Ann Intern Med. 2001 Dec 18;135(12):1061-73
pubmed: 11747385
N Engl J Med. 2016 May 19;374(20):1911-21
pubmed: 27043047
Am Heart J. 2009 Nov;158(5):792-8
pubmed: 19853700
JAMA. 2005 Dec 28;294(24):3093-100
pubmed: 16380589
Europace. 2016 Nov;18(11):1609-1678
pubmed: 27567465
J Am Coll Cardiol. 2018 Oct 23;72(17):2027-2036
pubmed: 30336826
Ann Thorac Surg. 2008 May;85(5):1556-62; discussion 1562-3
pubmed: 18442537
Circulation. 2014 Dec 2;130(23):e199-267
pubmed: 24682347